BG103334A - Antiviral vectors - Google Patents

Antiviral vectors

Info

Publication number
BG103334A
BG103334A BG103334A BG10333499A BG103334A BG 103334 A BG103334 A BG 103334A BG 103334 A BG103334 A BG 103334A BG 10333499 A BG10333499 A BG 10333499A BG 103334 A BG103334 A BG 103334A
Authority
BG
Bulgaria
Prior art keywords
vector particles
antiviral
vectors
antiviral vectors
consitructed
Prior art date
Application number
BG103334A
Other languages
Bulgarian (bg)
English (en)
Inventor
Alan Kingsman
Susan Kingsman
Original Assignee
Oxford Biomedica (Uk) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica (Uk) Limited filed Critical Oxford Biomedica (Uk) Limited
Publication of BG103334A publication Critical patent/BG103334A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16041Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16051Methods of production or purification of viral material
    • C12N2740/16052Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/15Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/50Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/60Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mushroom Cultivation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BG103334A 1996-10-17 1999-04-14 Antiviral vectors BG103334A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9621680.9A GB9621680D0 (en) 1996-10-17 1996-10-17 Lentiviral vectors
PCT/GB1997/002858 WO1998017816A1 (en) 1996-10-17 1997-10-17 Lentiviral vectors

Publications (1)

Publication Number Publication Date
BG103334A true BG103334A (en) 2000-06-30

Family

ID=10801598

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103334A BG103334A (en) 1996-10-17 1999-04-14 Antiviral vectors

Country Status (18)

Country Link
US (1) US6235522B1 (xx)
EP (1) EP0939827B1 (xx)
JP (1) JP2001502903A (xx)
KR (1) KR20000049250A (xx)
CN (1) CN1195864C (xx)
AT (1) ATE520783T1 (xx)
AU (1) AU737801B2 (xx)
BG (1) BG103334A (xx)
CA (1) CA2268271A1 (xx)
CZ (1) CZ137299A3 (xx)
GB (2) GB9621680D0 (xx)
HK (1) HK1018481A1 (xx)
HU (1) HUP0000442A3 (xx)
IL (1) IL128564A0 (xx)
NO (1) NO991742D0 (xx)
NZ (1) NZ334522A (xx)
PL (1) PL332876A1 (xx)
WO (1) WO1998017816A1 (xx)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924123B2 (en) * 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
WO1998051810A1 (en) 1997-05-13 1998-11-19 University Of North Carolina At Chapel Hill Lentivirus-based gene transfer vectors
FI112580B (fi) 1997-06-27 2003-12-15 Nokia Corp Kutsunsiirron reititys peruspalvelukohtaisesti
ATE298371T1 (de) 1997-09-24 2005-07-15 Univ California Nicht-primaten lentivirale vektoren und verpackungssysteme
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
EP1088086A4 (en) 1998-06-24 2003-01-08 Musc Found For Res Dev RIBOZYMES SPECIFIC TO TISSUE AND TARGET RNA
US6958226B1 (en) 1998-09-11 2005-10-25 The Children's Medical Center Corp. Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
EP1849873B1 (en) * 1999-04-29 2011-10-12 Gbp Ip, Llc Method and means for producing high titer, safe, recombinant lentivirus vectors
EP1083230A1 (en) * 1999-09-10 2001-03-14 Academisch Medisch Centrum Amsterdam Viral replicons and viruses dependent on inducing agents
WO2001030382A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
US6656706B2 (en) 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
EP1702983A3 (en) 2000-04-13 2007-01-10 Medical University of South Carolina Tissue-specific and pathogen-specific toxic agents, ribozymes, DNAzymes and antisense oligonucleotides and methods of use thereof
ATE346925T1 (de) 2000-05-10 2006-12-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
WO2001090391A2 (en) 2000-05-19 2001-11-29 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Utilization of non-viral sequences for minus-strand dna transfer and gene reconstitution
EP1326991A2 (en) * 2000-10-20 2003-07-16 Whitehead Institute For Biomedical Research Expression vectors and uses thereof
US7575924B2 (en) * 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US6712612B1 (en) 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
AU2002307393A1 (en) * 2001-04-20 2002-11-05 The Salk Institute For Biological Studies Inducible expression of transfected genes
US20030039636A1 (en) * 2001-05-01 2003-02-27 Genetix Pharmaceuticals, Inc. Novel self-inactivating (SIN) lentiviral vectors
WO2003012054A2 (en) 2001-08-02 2003-02-13 Institut Clayton De La Recherche Methods and compositions relating to improved lentiviral vector production systems
NZ532060A (en) * 2001-10-02 2005-11-25 Inst Clayton De La Rech Methods and compositions relating to restricted expression lentiviral vectors and their applications
PT1504108E (pt) 2002-02-01 2013-06-12 Oxford Biomedica Ltd Vetor lentiviral
US7786278B2 (en) 2002-04-09 2010-08-31 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
ATE424464T1 (de) * 2002-04-26 2009-03-15 Inst Nat Sante Rech Med Verbesserte chimäre glykoproteine und pseudotypisierte lentivirale vektoren
AU2003288686A1 (en) * 2002-11-22 2004-06-18 Institut Clayton De La Recherche Compositions and systems for the regulation of genes
WO2005030927A2 (en) * 2003-09-23 2005-04-07 Uab Research Foundation Methods and compositions for in vivo inflammation monitoring
DE602004032365D1 (de) * 2003-10-08 2011-06-01 Sanofi Pasteur Inc Modifizierter cea/b7-vektor
WO2005118809A2 (en) * 2004-04-29 2005-12-15 The University Of North Carolina At Chapel Hill Methods and compositions for enhancing cell adhesion properties
US20060292159A1 (en) * 2005-06-08 2006-12-28 Ranscht Barbara E Methods for the inhibition of neovascularization and cancer metastasis
GB201202516D0 (en) 2012-02-13 2012-03-28 Ucl Business Plc Materials and methods relating to packaging cell lines
WO2013184209A1 (en) 2012-06-04 2013-12-12 Ludwig Institute For Cancer Research Ltd. Mif for use in methods of treating subjects with a neurodegenerative disorder
KR101554678B1 (ko) 2012-10-19 2015-09-21 영남대학교 산학협력단 식물 바이러스를 이용한 식물체 형질전환을 위한 유전자 전달 시스템 및 이의 용도
HUE053136T2 (hu) 2013-02-15 2021-06-28 Bioverativ Therapeutics Inc Optimizált VIII. faktor gén
TWI582232B (zh) * 2013-03-13 2017-05-11 Zhong Li Microbubbles and methods for their manufacture
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
HUE059941T2 (hu) 2016-02-01 2023-01-28 Bioverativ Therapeutics Inc Optimalizált VIII-as faktor gének
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
AU2017341766A1 (en) 2016-10-12 2019-05-23 Bioverativ Usa Inc. Anti-C1s antibodies and methods of use thereof
US11332521B2 (en) 2016-11-07 2022-05-17 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
EP3645563A4 (en) 2017-06-27 2021-03-17 Neuracle Science Co., Ltd ANTI-FAM19A5 ANTIBODIES AND THEIR USES
EP3645039A4 (en) 2017-06-27 2021-05-05 Neuracle Science Co., Ltd USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS
US11560425B2 (en) 2017-06-27 2023-01-24 Neuracle Science Co., Ltd. Use of anti-FAM19A5 antibodies for treating cancers
KR102327698B1 (ko) 2017-06-27 2021-11-17 주식회사 뉴라클사이언스 녹내장의 치료를 위한 항-서열 유사성 19를 가진 패밀리, 멤버 a5 항체의 용도
EP3648776A4 (en) 2017-07-06 2021-04-07 The Medical College of Wisconsin, Inc. NEW IN VITRO AND IN VIVO ENRICHMENT STRATEGY TARGETING CHS-DERIVED LYMPHOCYTES TRANSDUCED BY A VECTOR FOR THE THERAPY OF DISORDERS
EP3694874A1 (en) 2017-10-11 2020-08-19 Bioverativ USA Inc. Methods of inducing complement activity
WO2019152692A1 (en) 2018-02-01 2019-08-08 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing factor viii
WO2019207513A1 (en) 2018-04-24 2019-10-31 Neuracle Science Co., Ltd. Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of neuropathic pain
US11970532B2 (en) 2018-05-10 2024-04-30 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
MX2020013923A (es) 2018-06-29 2021-03-29 Apitbio Inc Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.
KR20210093950A (ko) 2018-11-16 2021-07-28 네오이뮨텍, 인코퍼레이티드 Il-7 단백질 및 면역 관문 저해제의 조합으로 종양을 치료하는 방법
MX2021006648A (es) 2018-12-06 2021-07-07 Bioverativ Therapeutics Inc Uso de vectores lentivirales que expresan el factor ix.
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
WO2021067389A1 (en) 2019-09-30 2021-04-08 Bioverativ Therapeutics Inc. Lentiviral vector formulations
AU2021207586A1 (en) 2020-01-13 2022-07-21 Neoimmunetech, Inc. Method of treating a tumor with a combination of IL-7 protein and a bispecific antibody
WO2021151001A1 (en) 2020-01-22 2021-07-29 Outpace Bio, Inc. Chimeric polypeptides
WO2021151006A2 (en) 2020-01-22 2021-07-29 Outpace Bio, Inc. Chimeric polypeptides
WO2021158783A1 (en) 2020-02-05 2021-08-12 Washington University Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
KR20230074703A (ko) 2020-06-24 2023-05-31 바이오버라티브 테라퓨틱스 인크. 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법
US20230398216A1 (en) 2020-10-22 2023-12-14 Lyell Immunopharma, Inc. Chimeric activation receptors
WO2022093718A1 (en) 2020-10-26 2022-05-05 Neoimmunetech, Inc. Methods of inducing stem cell mobilization
EP4236989A1 (en) 2020-11-02 2023-09-06 NeoImmuneTech, Inc. Use of interleukin-7 for the treatment of coronavirus
KR20230104175A (ko) 2020-11-05 2023-07-07 네오이뮨텍, 인코퍼레이티드 Il-7 단백질과 뉴클레오타이드 백신의 조합물을 사용한 종양의 치료 방법
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
KR20240027676A (ko) 2021-06-02 2024-03-04 라이엘 이뮤노파마, 인크. Nr4a3-결핍 면역 세포 및 이의 용도
IL311725A (en) 2021-09-30 2024-05-01 Bioverativ Therapeutics Inc Nucleic acids encoding factor VIII polypeptides with reduced immunogenicity
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2024026490A1 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Polynucleotides encoding linked antigens and uses thereof
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604114A (en) * 1986-05-20 1997-02-18 Dana-Farber Cancer Institute Cis-acting repression sequences, cis-acting antirepression sequences, vectors, methods of preparation and use
WO1992021750A1 (en) * 1991-05-29 1992-12-10 THE UNITED STATES OF AMERICA, represented by THE SCRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES Eukaryotic expression vectors with regulation of rna processing
EP0759471A4 (en) * 1994-05-10 1997-10-15 Hisamitsu Pharmaceutical Co RECOMBINANT VECTOR OF HUMAN IMMUNODEFICIENCY VIRUS AND METHOD FOR THE PRODUCTION THEREOF
WO1995032300A1 (en) * 1994-05-23 1995-11-30 University Of Medicine & Dentistry Of New Jersey Selective biological destruction of tumor cells
US5693508A (en) * 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
DE69627644T2 (de) 1995-03-09 2004-02-19 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie
GB9510272D0 (en) 1995-05-22 1995-07-19 Isis Innovation Retroviral vectors
AU3212197A (en) * 1996-06-20 1998-01-07 Salk Institute For Biological Studies, The Modular assembly retroviral vectors and uses thereof

Also Published As

Publication number Publication date
EP0939827A1 (en) 1999-09-08
NO991742L (no) 1999-04-13
KR20000049250A (ko) 2000-07-25
US6235522B1 (en) 2001-05-22
HUP0000442A2 (hu) 2000-06-28
GB2331522A (en) 1999-05-26
GB2331522B (en) 2001-05-23
HK1018481A1 (en) 1999-12-24
WO1998017816A1 (en) 1998-04-30
CN1195864C (zh) 2005-04-06
GB9903117D0 (en) 1999-04-07
AU737801B2 (en) 2001-08-30
CZ137299A3 (cs) 1999-07-14
EP0939827B1 (en) 2011-08-17
JP2001502903A (ja) 2001-03-06
PL332876A1 (en) 1999-10-25
NO991742D0 (no) 1999-04-13
AU4712397A (en) 1998-05-15
CN1234075A (zh) 1999-11-03
CA2268271A1 (en) 1998-04-30
GB9621680D0 (en) 1996-12-11
IL128564A0 (en) 2000-01-31
HUP0000442A3 (en) 2001-09-28
ATE520783T1 (de) 2011-09-15
NZ334522A (en) 2001-11-30

Similar Documents

Publication Publication Date Title
BG103334A (en) Antiviral vectors
BG103397A (en) Retroviral vectors
GB9510272D0 (en) Retroviral vectors
MY119031A (en) Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hiv and other retroviruses
AU4880093A (en) Retrovirus from the HIV group and its use
CA2328404A1 (en) Novel lentiviral packaging cells
CA2011878A1 (en) Immunogenic regions on the e7 protein of human papillomavirus type 16
CA2051288A1 (en) Viral targeted destruction of neoplastic cells
DK631688A (da) 2',3'-dideoxy-2'-fluornucleosider, fremstillingen deraf samt praeparater indeholdende samme
EP0759471A4 (en) RECOMBINANT VECTOR OF HUMAN IMMUNODEFICIENCY VIRUS AND METHOD FOR THE PRODUCTION THEREOF
EP1262554A3 (en) Defective packaging non-oncoviral vectors based on mpmv and hiv
CA2185541A1 (en) Cytotoxic t-cell epitopes
EP0801575A4 (en) RETROVIRAL VECTORS FOR EXPRESSION IN EMBRYONIC CELLS
AU5686196A (en) Use of an "immunodeficiency-virus suppressing lymphokine (ISL)" to inhibit the replication of viruses, in particular of retroviruses
PT975783E (pt) "vectores retrovirais, processo para a sua producao e sua utilizacao para a transferencia de genes a celulas cd4-positivas"
DE3476784D1 (en) Therapeutic compositions endowed with antiviral activity
AU7289587A (en) Immunosuppressive factor from human immunodeficiency virus (hiv) or hiv infected cells or cell lines, its use, corresponding antibodies and their use
CA2141951A1 (en) Inhibition of retrovirus infection
AU4767093A (en) Peptides derived from an immunosuppressive region in the retroviral genome
AU1275095A (en) Antiviral composition of viral protein trans-dominant variants
AU7052291A (en) Genetic protection of animals against infection by the bovine leukemia virus, and provirus and recombinant virus derived from this virus
ES2007741A6 (es) Composiciones herbicidas a base de un herbicida de tipo glifosato y de un herbicida de tipo fenoxibenzoico, y procedimiento de tratamiento de vegetales indeseables por medio de estas composiciones.